CHRISTIAN PETER LARSEN, MD PHD
Radiology in Atlanta, GA
License number
Georgia 033853
Category
Radiology
Type
Transplant Surgery
License number
Georgia 033853
Category
Radiology
Type
Surgery
Address
Address
101 Wmb STE 5105, Atlanta, GA 30322
Phone
(404) 727-8466
(404) 727-3660 (Fax)
(404) 727-3660 (Fax)
Personal information
See more information about CHRISTIAN PETER LARSEN at radaris.comName
Address
Phone
155 Heritage Way, Covington, GA 30016
1170 Oakdale Rd NE, Atlanta, GA 30307
155 Heritage Way, Covington, GA 30016
55 Mockingbird Ln, Oxford, GA 30054
27 Redstart Ct, Monticello, GA 31064
Professional information
Dr. Christian P Larsen, Atlanta GA - MD (Doctor of Medicine)
Specialties:
General Surgery
Address:
Emory Clinic Transplant
1364 Clifton Rd NE SUITE 6400, Atlanta 30322
(404) 712-4444 (Phone)
Emory Clinic-Transplant
1365B Clifton Rd NE SUITE 6400, Atlanta 30322
(404) 778-5000 (Phone)
1364 Clifton Rd NE SUITE 6400, Atlanta 30322
(404) 712-4444 (Phone)
Emory Clinic-Transplant
1365B Clifton Rd NE SUITE 6400, Atlanta 30322
(404) 778-5000 (Phone)
Procedures:
Port Placements or Replacements, Renal Transplant and Nephrectomy
Conditions:
Hyperparathyroidism, Peripheral Vascular Disease (PAD, PVD)
Certifications:
General Surgery, 2001
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
Emory Clinic Transplant
1364 Clifton Rd NE SUITE 6400, Atlanta 30322
Emory Clinic-Transplant
1365B Clifton Rd NE SUITE 6400, Atlanta 30322
Chandler Regional Medical Center
1955 West Frye Rd, Chandler 85224
Emory University Hospital Midtown
550 Peachtree St North #East, Atlanta 30308
Emory University Hospital
1364 Clifton Rd North #East, Atlanta 30322
Grady Memorial Hospital
80 Jesse Hill Jr Dr South #East, Atlanta 30303
1364 Clifton Rd NE SUITE 6400, Atlanta 30322
Emory Clinic-Transplant
1365B Clifton Rd NE SUITE 6400, Atlanta 30322
Chandler Regional Medical Center
1955 West Frye Rd, Chandler 85224
Emory University Hospital Midtown
550 Peachtree St North #East, Atlanta 30308
Emory University Hospital
1364 Clifton Rd North #East, Atlanta 30322
Grady Memorial Hospital
80 Jesse Hill Jr Dr South #East, Atlanta 30303
Education:
Medical School
Emory University
Graduated: 1984
Stanford University School Med
Emory University Affiliated Hospitals Residency Program
Emory University Hospital
Emory University
Graduated: 1984
Stanford University School Med
Emory University Affiliated Hospitals Residency Program
Emory University Hospital
Vice President, Health Center Integration At Emory University Robert Woodruff Health Sciences Center
Position:
Dean at , Emory University School of Medicine, Chairman, Board of Directors at Emory Clinic, Vice President, Health Center Integration at Emory University Robert W. Woodruff Health Sciences Center
Location:
Greater Atlanta Area
Industry:
Hospital & Health Care
Work:
, Emory University School of Medicine
since Feb 2013
-
Dean
Emory Clinic
since Feb 2013
-
Chairman, Board of Directors
Emory University Robert W. Woodruff Health Sciences Center
since Jan 2013
-
Vice President, Health Center Integration
Emory University
2009 - Jan 2013
-
Professor and Chairman, Department of Surgery
Emory Healthcare
Feb 2009 - Jan 2013
-
Surgeon-in-Chief
Emory Healthcare
Jul 2000 - Jan 2013
-
Executive Director, Emory Transplant Center
Education:
University of Oxford 1987 - 1990
D. Phil. Emory University School of Medicine 1980 - 1984
M.D. Emory University 1976 - 1980
B.A., Chemistry
D. Phil. Emory University School of Medicine 1980 - 1984
M.D. Emory University 1976 - 1980
B.A., Chemistry
Interests:
Healthcare Delivery, Clinical and Academic Integration, Surgery
Christian Peter Larsen, Atlanta GA
Specialties:
Surgeon
Address:
1364 Clifton Rd Ne, Atlanta, GA 30322
Board certifications:
American Board of Surgery Certification in Surgery
Christian Peter Larsen, Atlanta GA
Specialties:
Surgery, Transplant Surgery
Work:
Emory University Hospital
1364 Clifton Rd Ne, Atlanta, GA 30322
1364 Clifton Rd Ne, Atlanta, GA 30322
Education:
Emory University(1984)
Methods For Inhibiting An Immune Response By Blocking The Gp39/Cd40 And Ctla4/Cd28/B7 Pathways And Compositions For Use Therewith
US Patent:
5916560, Jun 29, 1999
Filed:
Mar 20, 1997
Appl. No.:
8/821400
Inventors:
Christian P. Larsen - Atlanta GA
Alejandro A. Aruffo - Edmonds WA
Diane L. Hollenbaugh - Seattle WA
Peter S. Linsley - Seattle WA
Jeffrey A. Ledbetter - Seattle WA
Thomas C. Pearson - Atlanta GA
Alejandro A. Aruffo - Edmonds WA
Diane L. Hollenbaugh - Seattle WA
Peter S. Linsley - Seattle WA
Jeffrey A. Ledbetter - Seattle WA
Thomas C. Pearson - Atlanta GA
Assignee:
Bristol-Myers Squibb Company - Pinceton NJ
Emory University - Atlanta GA
Emory University - Atlanta GA
International Classification:
C07K 1628
US Classification:
4241541
Abstract:
The present invention provides a method for inhibiting an immune reponse and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand and preventing an endogenous molecule on a cell selected from the group consisting of CTLA4, CD28, and B7 antigens from binding its endogenous ligand. The prevention of such molecules from binding their ligand thereby blocks two independent signal pathways and inhibits the immune response resulting in transplanted tissue rejection.
Methods For Inhibiting An Immune Response By Blocking The Gp39/Cd40 And Ctla4/Cd28/B7 Pathways And Compositions For Use Therewith
US Patent:
2009018, Jul 23, 2009
Filed:
Sep 10, 2008
Appl. No.:
12/207997
Inventors:
Christian P. Larsen - Atlanta GA, US
Alejandro A. Aruffo - Sudbury MA, US
Diane L. Hollenbaugh - Seattle WA, US
Peter S. Linsley - Seattle WA, US
Jeffrey A. Ledbetter - Seattle WA, US
Thomas C. Pearson - Atlanta GA, US
Alejandro A. Aruffo - Sudbury MA, US
Diane L. Hollenbaugh - Seattle WA, US
Peter S. Linsley - Seattle WA, US
Jeffrey A. Ledbetter - Seattle WA, US
Thomas C. Pearson - Atlanta GA, US
International Classification:
A61K 39/395, A61K 38/16, A61P 37/06
US Classification:
4241441, 514 12
Abstract:
The present invention provides a method for inhibiting an immune response and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand and preventing an endogenous molecule on a cell selected from the group consisting of CTLA4, CD28, and B7 antigens from binding its endogenous ligand. The prevention of such molecules from binding their ligand thereby blocks two independent signal pathways and inhibits the immune response resulting in transplanted tissue rejection.
Methods For Inhibiting An Immune Response By Blocking The Gp39/Cd40 And Ctla4/Cd28/B7 Pathways And Compositions For Use Therewith
US Patent:
2002003, Mar 14, 2002
Filed:
May 22, 2001
Appl. No.:
09/862255
Inventors:
Christian Larsen - Atlanta GA, US
Alejandro Aruffo - Belle Mead NJ, US
Diane Hollenbaugh - Newtown PA, US
Peter Linsley - Seattle WA, US
Jeffrey Ledbetter - Seattle WA, US
Thomas Pearson - Atlanta GA, US
Alejandro Aruffo - Belle Mead NJ, US
Diane Hollenbaugh - Newtown PA, US
Peter Linsley - Seattle WA, US
Jeffrey Ledbetter - Seattle WA, US
Thomas Pearson - Atlanta GA, US
Assignee:
Bristol-Myers Squibb Company
International Classification:
A61K039/395
US Classification:
424/131100, 424/144100
Abstract:
The present invention provides a method for inhibiting an immune reponse and a method for inhibiting rejection of transplanted tissues. This method comprises preventing an endogenous molecule on a cell selected from the group consisting of gp39 and CD40 antigens from binding its endogenous ligand and preventing an endogenous molecule on a cell selected from the group consisting of CTLA4, CD28, and B7 antigens from binding its endogenous ligand. The prevention of such molecules from binding their ligand thereby blocks two independent signal pathways and inhibits the immune response resulting in transplanted tissue rejection.
Methods For Protecting Allogeneic Islet Transplant Using Soluble Ctla4 Mutant Molecules
US Patent:
7829534, Nov 9, 2010
Filed:
Oct 29, 2007
Appl. No.:
11/978701
Inventors:
Christian P. Larsen - Atlanta GA, US
Thomas C. Pearson - Atlanta GA, US
Andrew B. Adams - Atlanta GA, US
Robert J. Peach - San Diego CA, US
Peter S. Linsley - Seattle WA, US
Joseph Roy Naemura - Bellevue WA, US
Jurgen Bajorath - Bonn, DE
Thomas C. Pearson - Atlanta GA, US
Andrew B. Adams - Atlanta GA, US
Robert J. Peach - San Diego CA, US
Peter S. Linsley - Seattle WA, US
Joseph Roy Naemura - Bellevue WA, US
Jurgen Bajorath - Bonn, DE
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 38/16, C07K 14/705, C07K 16/46
US Classification:
514 12, 4241341, 530350, 5303873
Abstract:
The present invention is a method of inhibiting islet cell transplant rejection particular, to treat diabetes, such as type-1 and type-2 diabetes, by administering to a subject an effective amount of a soluble CTLA4 mutant molecule. One example of soluble CTLA4 mutant molecule is L104EA29YIg.
Methods For Protecting Allogeneic Islet Transplant Using Soluble Ctla4 Mutant Molecules
US Patent:
7304033, Dec 4, 2007
Filed:
May 23, 2002
Appl. No.:
10/155514
Inventors:
Christian P. Larsen - Atlanta GA, US
Thomas C. Pearson - Atlanta GA, US
Andrew B. Adams - Atlanta GA, US
Robert J. Peach - San Diego CA, US
Peter S. Linsley - Seattle WA, US
Joseph Roy Naemura - Bellevue WA, US
Jurgen Bajorath - Bonn, DE
Thomas C. Pearson - Atlanta GA, US
Andrew B. Adams - Atlanta GA, US
Robert J. Peach - San Diego CA, US
Peter S. Linsley - Seattle WA, US
Joseph Roy Naemura - Bellevue WA, US
Jurgen Bajorath - Bonn, DE
Assignee:
Bristol-Myers Squibb Company - Princeton NJ
International Classification:
A61K 38/16, C07K 14/00
US Classification:
514 12, 4241341, 530350, 5303873
Abstract:
The present invention is a method of inhibiting islet cell transplant rejection, particularly to treat diabetes, such as type-1 and type-2 diabetes, by administering to a subject an effective amount of a soluble CTLA4 mutant molecule. One example of a soluble CTLA4 mutant molecule is L104EA29YIg.
Use Of Mtor Inhibitors To Enhance T Cell Immune Responses
US Patent:
2011012, Jun 2, 2011
Filed:
Aug 5, 2009
Appl. No.:
13/057057
Inventors:
Rafi Ahmed - Atlanta GA, US
Christian P. Larsen - Atlanta GA, US
Koichi Araki - Atlanta GA, US
Christian P. Larsen - Atlanta GA, US
Koichi Araki - Atlanta GA, US
Assignee:
EMORY UNIVERSITY - Atlanta GA
International Classification:
A61K 39/12, A61K 39/02, A61K 39/00, A61P 31/04, A61P 31/10, A61P 31/12, A61P 33/00, A61P 35/00
US Classification:
4242041, 4242341, 4242651, 4242741, 4242771
Abstract:
It is disclosed herein that treatment of a subject with an mTOR inhibitor enhances antigen-specific T cell immune responses. Thus, provided herein is a method of enhancing an antigen-specific T cell response in a subject by administering to the subject a therapeutically effective amount of an mTOR inhibitor. The antigen can be any antigen, such as an antigen from a pathogen or a vaccine, or a tumor antigen. In some embodiments, the method further comprises administering to the subject a vaccine, such as a virus vaccine or a cancer vaccine. The mTOR inhibitor can be administered either before or after vaccination to enhance the quantity and quality of the T cell immune response and immunological memory. In some examples, the mTOR inhibitor is rapamycin or a rapamycin analog.